Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. - Test2 - elhamkhani - TriplyDB

Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia.

Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia.

http://www.wikidata.org/entity/Q53857165

about

Beta-thalassemia β-thalassemia intermedia: a clinical perspective A narrative review of peri-operative management of patients with thalassaemia Treating iron overload in patients with non-transfusion-dependent thalassemia Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia Pulmonary complications of sickle cell disease.Evidence for a novel mechanism independent of myocardial iron in β-thalassemia cardiac pathogenesis.Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature.Pulmonary hypertension in patients with hematological disorders following splenectomy.Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload.Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia Benefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertension Vascular endothelial dysfunction in β-thalassemia occurs despite increased eNOS expression and preserved vascular smooth muscle cell reactivity to NO Thalassaemia intermedia: an update.Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.Echocardiographic evaluation of thalassemia intermedia patients in Duhok, Iraq.Pulmonary hypertension in well-transfused thalassemia major patients Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders Heart Rate Variability as an Alternative Indicator for Identifying Cardiac Iron Status in Non-Transfusion Dependent Thalassemia Patients Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia.Pulmonary hypertension in sickle cell disease: relevance to children.Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management.Waiting to inhale: An exploratory review of conditions that may predispose to pulmonary hypertension and right heart failure in persons exposed to household air pollution in low- and middle-income countries.The prevention of adverse reactions to transfusions in patients with haemoglobinopathies: a proposed algorithm.Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension Acute cardiac decompensation in a patient with beta-thalassemia and diabetes mellitus following cessation of chelation therapy Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea Evaluation of cardiac function in patients with thalassemia intermedia.Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.Insight onto the pathophysiology and clinical complications of thalassemia intermedia.Heart disease in thalassemia intermedia.Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management.The surgeon and the patient with β-thalassaemia intermedia.Iron chelation therapy in the management of transfusion-related cardiac iron overload.

P2860

Q21202886-D24D7EB9-25CC-4255-A31B-863B153897A4 Q26828512-843CECA7-5D63-4102-963F-4E5CE6602CD0 Q27008301-EF4679D4-E76C-40F5-A3EF-124575D10781 Q27009463-BD429B6A-08A6-4777-B406-EFBA0EB610F4 Q28395387-6EBE18D0-FEF2-4BC2-95D5-01A2776EE78F Q30515769-AA7B13E5-37E2-4DD5-A147-BD5C645CC745 Q31110125-B7D11A0E-5304-4328-88B1-84816C19E2FE Q33165207-B8E7EC89-9898-40FB-90EE-53DF1027C161 Q33404045-B2A3ECD4-8D66-4DEF-A85F-D0CBED66A088 Q33843186-60E8EC2F-23D3-4071-BBD9-C372118C9B05 Q33993973-E8705778-7E8E-4B10-8863-F7895885D6C6 Q34094137-ECB518EB-484D-44FA-A9DB-EF60982E8917 Q34313817-3C49262D-973E-4AD1-AEFA-2CCC5AC5A3E2 Q34549431-93B057EC-2BCC-4686-9FDB-EC43B6D31742 Q34579250-BB20D313-931B-44DE-AD0C-EA2A7C3D31EA Q34692473-D600E4C7-B457-4443-9971-28F71AF77773 Q34748686-B2509DEC-0785-4A91-80E8-A43F09587175 Q34979478-DF836848-092D-4549-8AE0-0516259B17DD Q35346284-73E5F308-F59C-4097-B0D4-A828D4313D07 Q35528614-0740542F-F1E5-4EB9-BC95-A62C1DE9AD8C Q35590733-26696890-DCDB-4852-A0C0-C33BD03F5B11 Q35665822-088E868D-B6A9-4127-9651-32D502BED653 Q35743427-A293F05F-FE24-4B90-8E29-DB48ACF4C20C Q35750972-7A1AF1E6-F286-42AA-9F19-ABFF18B3FA4D Q35772015-BB6A45EE-E11C-4C18-B708-4EA770A09E23 Q36120873-A84B9188-92FE-40D5-A5AA-D700EA5BF7BC Q36419650-7FF04E61-A0BF-4645-9832-87922E64FD3D Q36477489-5C6B727F-FB0D-4BCF-A136-60F0C244A2B0 Q36841937-4E1DE5CA-832E-42B9-AF60-58277AADA06E Q37059214-10A7D332-BCD4-4643-A378-17D63CC5B68B Q37144856-02939916-E3BF-4C5D-A89C-F4F0FDF6E45E Q37319367-AF0F7DE6-EC22-4B7B-9FB2-D4462FA5C4EC Q37494096-21C52EC3-6EBB-443C-B1D8-DE029D1C506F Q37560087-D9B6AAD9-0C0E-472B-8D77-0ADA92F0F375 Q37565002-DAEE46AD-8A17-485C-8193-6A29B106F9F3 Q37650433-D348BC63-A8A8-4791-9400-0DFD72900ECC Q37650441-80ECEF37-4C9A-4803-BC7A-5343B7ECFD45 Q37854465-EC9BFD80-18D0-492B-9F9A-9C7CD3E94D3D Q37863611-B14FB9DB-33C6-4F16-B473-B87C242EA64C Q37992181-08841F77-5EDA-42A5-AED5-16D842A2FFB0

P2860

Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia.

http://www.wikidata.org/entity/Q53857165

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Thalassemia heart disease: a c ...... or and thalassemia intermedia.

@en

Thalassemia heart disease: a c ...... or and thalassemia intermedia.

@nl

type

label

Thalassemia heart disease: a c ...... or and thalassemia intermedia.

@en

Thalassemia heart disease: a c ...... or and thalassemia intermedia.

@nl

prefLabel

Thalassemia heart disease: a c ...... or and thalassemia intermedia.

@en

Thalassemia heart disease: a c ...... or and thalassemia intermedia.

@nl

P1433

Q53857165-F88013CB-C2C4-4787-9193-E6CFBD3ED5E9

P1476

Q53857165-D063D9EC-3D99-498F-AF16-CC9393BE5E01

P2093

Q53857165-47E9660B-B8DB-421E-98B7-EA31B0EB9F80

Q53857165-4F4CDD8F-4C8A-4F70-A3AC-4B83F02C687D

Q53857165-82CD1E47-5DF5-4AA6-A922-653409777175

Q53857165-B1BEF01B-9377-41E3-AFFC-7729C318560C

Q53857165-BC77953A-6BE2-4390-B6A2-150F6061B5FD

Q53857165-C32101BE-7D40-4433-9811-904862ECDE58

Q53857165-DE2B137C-B052-434D-BB15-E8E3DC6337F7

P304

Q53857165-E8E0B732-5503-4B99-9855-D92275AFAF61

P31

Q53857165-C361E391-891B-43EB-994F-D56F289FB911

P356

Q53857165-0095920F-3604-4125-9418-0506065ACCDA

P407

Q53857165-CE89B13F-7FF7-442A-92A5-3F9D51E0FF5B

P433

Q53857165-24243815-6CE2-4B49-9CA4-FA8D2FE8EFB1

P478

Q53857165-036657FB-8995-4AB2-96CC-C2F051F0BDA5

P577

Q53857165-A370A160-3FC5-4DFA-A33F-442F1A2E6D1F

P698

Q53857165-B3CBDBE2-4526-4D1A-95CC-3BDC5C431E3A

P356

CHEST.127.5.1523

P1433

P1476

Thalassemia heart disease: a c ...... or and thalassemia intermedia.

@en

P2093

Athanasios Aessopos

http://www.w3.org/2001/XMLSchema#string

Dimitrios Farmakis

http://www.w3.org/2001/XMLSchema#string

Ioannis Moyssakis

http://www.w3.org/2001/XMLSchema#string

Maria Tsironi

http://www.w3.org/2001/XMLSchema#string

Markisia Karagiorga

http://www.w3.org/2001/XMLSchema#string

Spyros Deftereos

http://www.w3.org/2001/XMLSchema#string

Stergios Tassiopoulos

http://www.w3.org/2001/XMLSchema#string

P304

1523-1530

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1378/CHEST.127.5.1523

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15888823

http://www.w3.org/2001/XMLSchema#string